These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29076913)

  • 41. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma.
    Zhang X; Fan W; Hu YY; Li ZM; Xia ZJ; Lin XP; Zhang YR; Liang PY; Li YH
    Chin J Cancer; 2015 Jun; 34(6):264-71. PubMed ID: 26063296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma.
    Uluköylü Mengüç M; Mehtap Ö; Dağlıöz Görür G; Birtaş Ateşoğlu E; Gedük A; Ünal S; Tarkun P; Hacıhanefioğlu A
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e922-e927. PubMed ID: 34353778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
    Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
    Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
    Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
    J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
    Qin C; Yang S; Sun X; Xia X; Li C; Lan X
    Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
    Ordu C; Selcuk NA; Akosman C; Eren OO; Altunok EC; Toklu T; Oyan B
    Asian Pac J Cancer Prev; 2015; 16(1):321-6. PubMed ID: 25640373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
    Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
    Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Prognostic Utility of
    Li C; Yu H; Chen X; Han S; Peng S; Lei T; Yang H
    Front Oncol; 2022; 12():772773. PubMed ID: 35677166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
    Xie M; Wu K; Liu Y; Jiang Q; Xie Y
    Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma.
    Liao CC; Qin YY; Tan XH; Hu JJ; Tang Q; Rong Y; Cen H; Li LQ
    Onco Targets Ther; 2017; 10():5727-5738. PubMed ID: 29238205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
    Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.